Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Other financing activities: 2009-2024

Historic Other financing activities for Lifecore Biomedical (LFCR) over the last 8 years, with May 2024 value amounting to $107,000.

  • Lifecore Biomedical's Other financing activities fell 95.51% to $107,000 in Q2 2024 from the same period last year, while for May 2024 it was $6.8 million, marking a year-over-year increase of 1.04%. This contributed to the annual value of $435,000 for FY2025, which is 88.31% up from last year.
  • As of Q2 2024, Lifecore Biomedical's Other financing activities stood at $107,000, which was down 95.51% from $2.4 million recorded in Q2 2023.
  • In the past 5 years, Lifecore Biomedical's Other financing activities registered a high of $8.4 million during Q1 2021, and its lowest value of $37,000 during Q1 2022.
  • In the last 3 years, Lifecore Biomedical's Other financing activities had a median value of $652,000 in 2022 and averaged $1.4 million.
  • Its Other financing activities has fluctuated over the past 5 years, first plummeted by 99.56% in 2022, then surged by 9,816.22% in 2023.
  • Lifecore Biomedical's Other financing activities (Quarterly) stood at $725,000 in 2020, then crashed by 74.22% to $132,000 in 2021, then fell by 24.97% to $652,000 in 2022, then soared by 265.18% to $2.4 million in 2023, then tumbled by 95.51% to $107,000 in 2024.
  • Its last three reported values are $107,000 in Q2 2024, $2.4 million for Q2 2023, and $3.7 million during Q1 2023.